Cite
HARVARD Citation
Younes, A. et al. (n.d.). Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet oncology. 17 (9), pp. 1283-1294. [Online].